US Patent Issued to Bristol-Myers Squibb on Nov. 25 for "Substituted N(-methyl-D3)pyridazine-3-carboxamide or M-(methyl-D3)-nicotinamide compounds as IL-12, IL-23 and/or IFNAlpha modulators" (New Jersey, California Inventors)

ALEXANDRIA, Va., Nov. 25 -- United States Patent no. 12,479,831, issued on Nov. 25, was assigned to Bristol-Myers Squibb Co. (Princeton, N.J.).

"Substituted N(-methyl-D3)pyridazine-3-carboxamide or M-(methyl-D3)-nicotinamide compounds as IL-12, IL-23 and/or IFNAlpha modulators" was invented by Chunjian Liu (Pennington, N.J.), James Lin (Lawrenceville, N.J.) and David S. Weinstein (San Diego).

According to the abstract* released by the U.S. Patent & Trademark Office: "There are disclosed compounds of the following formula I or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduct...